"10.1371_journal.pone.0053067","plos one","2013-01-02T00:00:00Z","Shih-Wen Lin; Arpita Ghosh; Carolina Porras; Sarah C Markt; Ana Cecilia Rodriguez; Mark Schiffman; Sholom Wacholder; Troy J Kemp; Ligia A Pinto; Paula Gonzalez; Nicolas Wentzensen; Mark T Esser; Katie Matys; Ariane Meuree; Wim Quint; Leen-Jan van Doorn; Rolando Herrero; Allan Hildesheim; Mahboobeh Safaeian; Costa Rican Vaccine Trial Group","Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America; Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Guanacaste, Costa Rica; Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America; HPV Immunology Laboratory, SAIC-Frederick Inc., NCI-Frederick, Frederick, Maryland, United States of America; MedImmune, Gaithersburg, Maryland, United States of America; PPD Vaccines and Biologics Center of Excellence, Wayne, Pennsylvania, United States of America; GlaxoSmithKline Biologicals, Rixensart, Belgium; DDL Diagnostic Laboratory, Voorburg, The Netherlands; Prevention and Implementation Group, International Agency for Research on Cancer, Lyon, France","¶ Membership of the Costa Rican Vaccine Trial Group is provided in the Acknowledgments","This study was conducted with the support from the Ministry of Health of Costa Rica. Vaccine was provided for the trial by GlaxoSmithKline Biologicals (GSK), under a Clinical Trials Agreement with the NCI. GSK also provided support for aspects of the trial associated with regulatory submission needs of the company under FDA BB-IND 7920. One or more of the authors are employed by a commercial company. These include: Mark T. Esser, MedImmune; Katie Matys, PPD Vaccines and Biologics Center of Excellence; Ariane Meuree, GlaxoSmithKline Biologicals; Wim Quint, DDL Diagnostic Laboratory; and Leen-Jan van Doorn, DDL Diagnostic Laboratory. No other financial disclosures were reported. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","01","Shih-Wen Lin","SWL",20,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
